Please enable JavaScript to continue using this application.

Compare $CADL vs $HUMA | Chartloom

Compare

$CADL vs $HUMA

Candel Therapeutics Inc · Humacyte Inc

CADL

Candel Therapeutics Inc

HUMA

Humacyte Inc

Compare $CADL vs $HUMA

Comparing Candel Therapeutics Inc and Humacyte Inc

CADLCandel Therapeutics Inc

HUMAHumacyte Inc

CADLCandel Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

82.7%

52W performance

57.8%

FCF yield

-7.9%

HUMAHumacyte Inc

Market cap

$109M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

14.62x

Rev growth (TTM)

159.3%

YTD performance

-58.4%

52W performance

-76.0%

FCF yield

-89.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CADL

HUMA

Detailed metrics comparison

CADL

Candel Therapeutics Inc

HUMA

Humacyte Inc

Market Cap

CADL$728M

HUMA$109M

Enterprise Value

CADL$575M

HUMA$96M

Price

CADL$9.94

HUMA$0.41

P/E Ratio

CADLN/A

HUMAN/A

P/S Ratio

CADL6,281.93x

HUMA51.53x

EV/Sales

CADL5,042.14x

HUMA45.06x

EV/EBITDA

CADL0.00x

HUMA0.00x

P/B Ratio

CADL6.18x

HUMA4.63x

P/FCF Ratio

CADLN/A

HUMAN/A

EV/FCF

CADL-10.02x

HUMA-0.98x

PEG Ratio

CADLN/A

HUMAN/A

Forward P/E (NTM)

CADLN/A

HUMAN/A

Forward P/S (NTM)

CADLN/A

HUMA14.62x

Revenue (TTM)

CADL$0

HUMA$2M

Revenue Growth (YoY)

CADLN/A

HUMA159.3%

Forward Rev Growth

CADL371.1%

HUMA520.3%

Gross Margin (TTM)

CADL0.0%

HUMA-494.6%

Operating Margin (TTM)

CADL0.0%

HUMA0.0%

EBITDA Margin (TTM)

CADL0.0%

HUMA-4900.0%

Net Margin (TTM)

CADL0.0%

HUMA-4560.8%

FCF Margin (TTM)

CADLN/A

HUMA-4599.7%

Net Income (TTM)

CADL$-89M

HUMA$-97M

FCF (TTM)

CADL$-57M

HUMA$-98M

EPS (TTM)

CADL-$1.19

HUMA-$0.41

ROE (TTM)

CADL-8938.0%

HUMA-51675.0%

ROA (TTM)

CADL-5631.0%

HUMA-8476.0%

ROIC (TTM)

CADL-6512.0%

HUMA-9784.0%

Cash

CADL$202M

HUMA$80M

Debt

CADL$48M

HUMA$66M

Net Cash/Debt

CADL$154M

HUMA$14M

Current Ratio (TTM)

CADL16.09x

HUMA6.21x

Quick Ratio (TTM)

CADL15.89x

HUMA5.38x

Debt/Equity (TTM)

CADL0.38x

HUMA2.12x

Debt/Assets (TTM)

CADL0.0%

HUMA0.0%

Interest Coverage (TTM)

CADLN/A

HUMAN/A

Net Debt/EBITDA (TTM)

CADL0.00x

HUMA0.00x

Beta

CADL-0.28

HUMA2.76

52W Performance

CADL57.8%

HUMA-76.0%

YTD Performance

CADL82.7%

HUMA-58.4%

% from 52W High

CADL-29.0%

HUMA-78.6%

% from 52W Low

CADL128.5%

HUMA3.7%

Asset Turnover (TTM)

CADL0.00x

HUMA0.02x

FCF Yield (TTM)

CADL-7.9%

HUMA-89.3%

Earnings Yield (TTM)

CADL-12.2%

HUMA-88.5%

Dividend Yield (TTM)

CADLN/A

HUMAN/A

Rule of 40

CADL0.0

HUMA-4,440.4

EV/GP/RG

CADLN/A

HUMAN/A

Ticker research

View CADL research View HUMA research

Metric	CADL Candel Therapeutics Inc	HUMA Humacyte Inc
Market & Valuation
Market Cap	$728M	$109M
Enterprise Value	$575M	$96M
Price	$9.94	$0.41
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	51.53x
EV/Sales	5,042.14x	45.06x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.18x	4.63x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-0.98x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	14.62x
Revenue & Growth
Revenue (TTM)	$0	$2M
Revenue Growth (YoY)	N/A	159.3%
Forward Rev Growth	371.1%	520.3%
Profitability
Gross Margin (TTM)	0.0%	-494.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-4900.0%
Net Margin (TTM)	0.0%	-4560.8%
FCF Margin (TTM)	N/A	-4599.7%
Net Income (TTM)	$-89M	$-97M
FCF (TTM)	$-57M	$-98M
EPS (TTM)	-$1.19	-$0.41
ROE (TTM)	-8938.0%	-51675.0%
ROA (TTM)	-5631.0%	-8476.0%
ROIC (TTM)	-6512.0%	-9784.0%
Financial Health
Cash	$202M	$80M
Debt	$48M	$66M
Net Cash/Debt	$154M	$14M
Current Ratio (TTM)	16.09x	6.21x
Quick Ratio (TTM)	15.89x	5.38x
Debt/Equity (TTM)	0.38x	2.12x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	2.76
52W Performance	57.8%	-76.0%
YTD Performance	82.7%	-58.4%
% from 52W High	-29.0%	-78.6%
% from 52W Low	128.5%	3.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-7.9%	-89.3%
Earnings Yield (TTM)	-12.2%	-88.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-4,440.4
EV/GP/RG	N/A	N/A
Ticker research	View CADL research	View HUMA research

Valuation

P/S Ratio

HUMA

51.53x

CADL

6,281.93x

EV/FCF

CADL

-10.02x

HUMA

-0.98x

Growth & revenue

Revenue Growth TTM

HUMA

159.3%

Forward Revenue Growth

HUMA

520.3%

CADL

371.1%

Profitability & performance

Gross Margin

CADL

0.0%

HUMA

-494.6%

ROE

CADL

-8938.0%

HUMA

-51675.0%

FCF Yield %

CADL

-7.9%

HUMA

-89.3%

52-Week Performance

CADL

57.8%

HUMA

-76.0%

Detailed metrics comparison

CADL

Candel Therapeutics Inc

HUMA

Humacyte Inc

Market Cap

CADL$728M

HUMA$109M

Enterprise Value

CADL$575M

HUMA$96M

Price

CADL$9.94

HUMA$0.41

P/E Ratio

CADLN/A

HUMAN/A

P/S Ratio

CADL6,281.93x

HUMA51.53x

EV/Sales

CADL5,042.14x

HUMA45.06x

EV/EBITDA

CADL0.00x

HUMA0.00x

P/B Ratio

CADL6.18x

HUMA4.63x

P/FCF Ratio

CADLN/A

HUMAN/A

EV/FCF

CADL-10.02x

HUMA-0.98x

PEG Ratio

CADLN/A

HUMAN/A

Forward P/E (NTM)

CADLN/A

HUMAN/A

Forward P/S (NTM)

CADLN/A

HUMA14.62x

Revenue (TTM)

CADL$0

HUMA$2M

Revenue Growth (YoY)

CADLN/A

HUMA159.3%

Forward Rev Growth

CADL371.1%

HUMA520.3%

Gross Margin (TTM)

CADL0.0%

HUMA-494.6%

Operating Margin (TTM)

CADL0.0%

HUMA0.0%

EBITDA Margin (TTM)

CADL0.0%

HUMA-4900.0%

Net Margin (TTM)

CADL0.0%

HUMA-4560.8%

FCF Margin (TTM)

CADLN/A

HUMA-4599.7%

Net Income (TTM)

CADL$-89M

HUMA$-97M

FCF (TTM)

CADL$-57M

HUMA$-98M

EPS (TTM)

CADL-$1.19

HUMA-$0.41

ROE (TTM)

CADL-8938.0%

HUMA-51675.0%

ROA (TTM)

CADL-5631.0%

HUMA-8476.0%

ROIC (TTM)

CADL-6512.0%

HUMA-9784.0%

Cash

CADL$202M

HUMA$80M

Debt

CADL$48M

HUMA$66M

Net Cash/Debt

CADL$154M

HUMA$14M

Current Ratio (TTM)

CADL16.09x

HUMA6.21x

Quick Ratio (TTM)

CADL15.89x

HUMA5.38x

Debt/Equity (TTM)

CADL0.38x

HUMA2.12x

Debt/Assets (TTM)

CADL0.0%

HUMA0.0%

Interest Coverage (TTM)

CADLN/A

HUMAN/A

Net Debt/EBITDA (TTM)

CADL0.00x

HUMA0.00x

Beta

CADL-0.28

HUMA2.76

52W Performance

CADL57.8%

HUMA-76.0%

YTD Performance

CADL82.7%

HUMA-58.4%

% from 52W High

CADL-29.0%

HUMA-78.6%

% from 52W Low

CADL128.5%

HUMA3.7%

Asset Turnover (TTM)

CADL0.00x

HUMA0.02x

FCF Yield (TTM)

CADL-7.9%

HUMA-89.3%

Earnings Yield (TTM)

CADL-12.2%

HUMA-88.5%

Dividend Yield (TTM)

CADLN/A

HUMAN/A

Rule of 40

CADL0.0

HUMA-4,440.4

EV/GP/RG

CADLN/A

HUMAN/A

Ticker research

View CADL research View HUMA research

Metric	CADL Candel Therapeutics Inc	HUMA Humacyte Inc
Market & Valuation
Market Cap	$728M	$109M
Enterprise Value	$575M	$96M
Price	$9.94	$0.41
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	51.53x
EV/Sales	5,042.14x	45.06x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.18x	4.63x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-0.98x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	14.62x
Revenue & Growth
Revenue (TTM)	$0	$2M
Revenue Growth (YoY)	N/A	159.3%
Forward Rev Growth	371.1%	520.3%
Profitability
Gross Margin (TTM)	0.0%	-494.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-4900.0%
Net Margin (TTM)	0.0%	-4560.8%
FCF Margin (TTM)	N/A	-4599.7%
Net Income (TTM)	$-89M	$-97M
FCF (TTM)	$-57M	$-98M
EPS (TTM)	-$1.19	-$0.41
ROE (TTM)	-8938.0%	-51675.0%
ROA (TTM)	-5631.0%	-8476.0%
ROIC (TTM)	-6512.0%	-9784.0%
Financial Health
Cash	$202M	$80M
Debt	$48M	$66M
Net Cash/Debt	$154M	$14M
Current Ratio (TTM)	16.09x	6.21x
Quick Ratio (TTM)	15.89x	5.38x
Debt/Equity (TTM)	0.38x	2.12x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	2.76
52W Performance	57.8%	-76.0%
YTD Performance	82.7%	-58.4%
% from 52W High	-29.0%	-78.6%
% from 52W Low	128.5%	3.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-7.9%	-89.3%
Earnings Yield (TTM)	-12.2%	-88.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-4,440.4
EV/GP/RG	N/A	N/A
Ticker research	View CADL research	View HUMA research